Stereotaxis announced on January 30, 2025, that it has received the first firm order for its latest generation robotic system, GenesisX™, from a pioneering European hospital. This order marks a critical milestone as the company advances towards the full commercial launch of its innovative technology.
GenesisX represents a significant advancement in endovascular surgical robotics, building on the established benefits of Robotic Magnetic Navigation while enhancing accessibility for healthcare providers. The system features smaller magnets and integrated magnetic shielding, eliminating the need for structural modifications or extensive room-based shielding.
The new system requires no structural anchoring, operates on standard power outlets, and has an 80% smaller system cabinet, making it more compact and easier to install. GenesisX obtained CE Mark in Europe in 2024 and has been submitted to the FDA for 510(k) clearance in the United States, with plans for a full launch following regulatory approvals and supply chain preparations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.